Italian Biocatalysis Center, Department of Drug Sciences, University of Pavia, Via Taramelli 12, 27100 Pavia, Italy.
Appl Microbiol Biotechnol. 2012 Sep;95(6):1491-500. doi: 10.1007/s00253-011-3817-y. Epub 2012 Jan 8.
We describe the rational design of a new efficient biocatalyst and the development of a sustainable green process for the synthesis of cephalosporins bearing a NH₂ group on the acyl side chain. The new biocatalyst was developed starting from the WT penicillin acylase (PA) from Escherichia coli by combining enzyme mutagenesis, in position α146 and β24 (βF24A/αF146Y), and immobilization on an appropriate modified industrial support, glyoxyl Eupergit C250L. The obtained derivative was used in the kinetically controlled synthesis of cephalexin, cefprozil and cefaclor and compared to the WT-PA and an already described mutant, PA-βF24A, with improved properties. The new biocatalyst posses a very high ratio between the rates of the synthesis and two undesired hydrolyses (acylating ester and the amidic product). In particular, a very low amidase activity was observed with PA-βF24A/αF146Y and, consequently, the hydrolysis of the produced antibiotic was avoided during the process. Taking advantage of this property, higher conversions in the synthesis of cephalexin (99% versus 76%), cefaclor (99% versus 65%) and cefprozil (99% versus 60%) were obtained compared to the WT enzyme. Furthermore, the new mutant also show a higher synthetic activity compared to PA-βF24A immobilized on the same support, allowing the maximum yields to be achieved in very short reaction times. The production of cephalexin with the immobilized βF24A/αF146Y acylase has been developed on a pre-industrial scale (30 l). After 20 cycles, the average yield was 93%. The biocatalyst showed good stability properties and no significant decrease in performance.
我们描述了一种新的高效生物催化剂的合理设计,并开发了一种可持续的绿色工艺,用于合成带有酰基侧链上 NH₂ 基团的头孢菌素。新的生物催化剂是从大肠杆菌来源的 WT 青霉素酰化酶(PA)开始开发的,通过在位置 α146 和 β24(βF24A/αF146Y)进行酶突变,并固定在适当的改性工业载体上,即乙二醛 Eupergit C250L。所得衍生物用于头孢氨苄、头孢丙烯和头孢克洛的动力学控制合成,并与 WT-PA 和已描述的突变体 PA-βF24A 进行比较,后者具有改善的性质。新型生物催化剂在合成和两种不需要的水解(酰化酯和酰胺产物)之间具有非常高的速率比。特别是,PA-βF24A/αF146Y 的酰胺酶活性非常低,因此在该过程中避免了产生的抗生素的水解。利用这一特性,与 WT 酶相比,头孢氨苄(99%对 76%)、头孢克洛(99%对 65%)和头孢丙烯(99%对 60%)的合成转化率更高。此外,与固定在相同载体上的 PA-βF24A 相比,新型突变体的合成活性也更高,从而在非常短的反应时间内达到最高产率。用固定化βF24A/αF146Y 酰化酶生产头孢氨苄已在预工业化规模(30 l)上进行。经过 20 个循环,平均收率为 93%。该生物催化剂具有良好的稳定性,性能没有明显下降。